Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration

Journal of Analytical Toxicology

Volumn 21, Issue 2, 1997, Pages 105-114

  Skopp, Gisela ^a,b   Ganssmann, Beate ^a   Cone, Edward J ^c   Aderjan, Rolf ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Institute of Legal Medicine   (Germany)

^c NIDA Addiction Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; MORPHINE; MORPHINE 6 ACETATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG HALF LIFE; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; LIPOPHILICITY; MALE; MASS SPECTROMETRY; RANDOMIZED CONTROLLED TRIAL; SOLID PHASE EXTRACTION;

EID: 0030946338     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/21.2.105     Document Type: Article

References (34)

1. D. Westerling, C. Persson, and P. Höglund. Plasma concentration of morphine, morphine-3-glucuronide, and morphine-6-glucuronide after intravenous and oral administration to healthy volunteers: Relationship to nonanalgesic actions. Ther. Drug Monitor. 17: 287-301 (1995).
2. J. Hasselström and J. Säwe. Morphine pharmacokinetics and metabolism in humans. Clin. Pharmacokinet. 24(4): 344-54 (1993).
3. N. Babul and A.C. Darke. Disposition of morphine and its glucuronide metabolites after oral and rectal administration: Evidence of route specificity. Clin. Pharmacol. Ther. 54(3): 286-92 (1993).
4. P.A. Glare and T.D. Walsh. Clinical pharmacokinetics of morphine. Ther. Drug Monitor 13: 1-23 (1991).
5. G.W. Aherne, E.M. Piall, and R.G. Twycross. Serum morphine concentration after oral administration of diamorphine-hydrochloride and morphine sulfate. Br. J. Clin. Pharmacol. 8: 577-80 (1979).
6. C.E. Inturrisi, M.B. Max, K.M. Foley, M. Schultz, S.-U. Shin, and R.W. Houde. The pharmacokinetics of heroin in patients with chronic pain. N. Engl. J. Med. 310(19): 1213-17.
7. E.L. Way, J.W. Kemp, J.M. Young, and D.R. Grassetti. The pharmacologic effects of heroin in relationship to its rate of biotransformation. J. Pharmacol. Exp. Ther. 129: 144-54 (1960).
8. U. Boerner, S. Abott, and R.L Roe. The metabolism of morphine and heroin in man. Drug Metab. Rev. 4: 39-73 (1975).
9. A.J. Jenkins, J.M. Oyler, and E.J. Cone. Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. J. Anal. Toxicol. 19: 359-74 (1995).
10. A.J. Jenkins, R.M. Keenan, J.E. Henningfield, and E.J. Cone. Pharmacokinetics and pharmacodynamics of smoked heroin. J. Anal. Toxicol. 18: 317-30 (1994).
11. J. Sawynok. The therapeutic use of heroin: A review of the pharmacological literature. Can. J. Physiol. Pharmacol. 64: 1-6 (1986).
12. J.R. Osborne, S.P. Joel, D. Trew, and M.L. Slevin. Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite M6G. Clin. Pharm. Ther. 47: 12-19 (1990).
13. J.F. French and J. Safford. AIDS and intranasal heroin. Lancet 1: 1082 (1989).
14. E. Cone, B.A. Holicky, T.M. Grant, W.D. Darwin, and B.A. Goldberger. Pharmacokinetics and pharmacodynamics of intranasal "snorted" heroin. J. Anal. Toxicol. 17: 327-37 (1993).
15. B.A. Goldberger, W.D. Darwin, T.M. Grant, A.A. Allen, Y.H. Caplan, and E.J. Cone. Measurement of heroin and its metabolites by isotope-dilution electron-impact mass spectrometry. Clin. Chem. 39: 670-75 (1993).
16. R. Aderjan, S. Hofmann, G. Schmitt, and G. Skopp. Morphine and morphine glucuronides in plasma of heroin consumers and in heroin-related deaths determined by HPLC with native fluorescence. J. Anal. Toxicol. 19: 163-68 (1995).
17. G.L. Long and J.D. Wineforder. Limit of detection. Anal. Chem. 55: 712A-19A (1983).
18. G. Schmitt, M. Bogusz, R. Aderjan, and C. Meyer. Zum Nachweis von Morphin und Codein in Blutproben mit GC/MS (NC und PCI) und zur Unterscheidung einer Codeinaufnahme von Heroin-oder Morphinkonsum. Z. Rechtsmed. 103: 513-21 (1990).
19. T.A. Shepard, R.H. Reuning, and L.J. Aarons. Interpretation of area under the curve measurements for drugs subject to enterohepatic cycling. J. Pharm. Sci. 74: 227-28 (1985).
20. R.C. Baselt and R.H. Cravey. Disposition of Toxic Drugs and Chemicals in Man. Yearbook Medical Publishers, Chicago, IL, 1989.
21. S.L. Underwood, D. Lingham, J. Pearson, and D. Raeburn. A novel technique for the administration of bronchodilator drugs formulated as dry powders to the anaestetized guinea pig. J. Pharmacol. Meth. 26: 203-10 (1991).
22. C.A. Huang. Mechanism of nasal absorption of drugs I: Physicochemical parameters influencing the rate of in situ nasal absorption in rats. J. Pharm. Sci. 74: 688 (1985).
23. C. McMartin. Analysis of structural requirements from the nasal cavity. J. Pharm. Sci. 76: 535 (1987).
24. M. Gibaldi. Biopharmaceutics and Clinical Pharmacokinetics. 4th ed., Lea & Febiger, Malvern, PA, 1991.
25. G.R. Nakamura, J.L. Thornton, and T.T. Noguchi. Kinetics of heroin deacetylation in aqueous alkaline solution and in human plasma and whole blood. J. Chromatogr. 110: 81-89 (1975).
26. O. Lockridge, N. Mottershow-Jackson, H.W. Eckerson, and B.N. La Du. Hydrolysis of diacetylmorphine (heroin) by human plasma cholinesterase. J. Pharmacol. Exp. Ther. 215: 1-8 (1980).
27. P.M. Koopman-Kimenai, T.B. Vree, L.H.D.J. Bonn, and R. Dirksen. The bioavailability of intramuscularly administered nicomorphine (Vilan) with its metabolites and glucuronide conjugates in surgical patients. Int. J. Clin. Pharmacol. Ther. 33: 442-48 (1995).
28. M.T. Smith, J.A. Watt, and T. Crammond. Morphine-3-glucuronide, a potent agonist in opiate analgesia. Life Sci. 47: 579-85 (1990).
29. J.S. Morley. Paradoxical pain. Lancet 340: 1045 (1992).
30. J.A. Owen and K. Nakatsu. Diacetylmorphine (heroin) hydrolysis in human blood. Can J. Physiol. Pharmacol. 61: 870-75 (1983).
31. B.E. Dahlström and L.K. Paalzow. Pharmacokinetic interpretation of the enterohepatic circulation and first pass elimination of morphine in the rat. J. Pharmacokinet. Biopharm. 6: 505-19 (1978).
32. E. Jacqz, S. Ward, R. Johnson, S. Schenker, and J. Gerkens. Extra-hepatic glucuronidation of morphine in the dog. Drug Metab. Dispos. 14: 627-30 (1986).
33. P. Carrupt, B. Testa, A. Bechalany, N. El Tayar, P. Descas, and D. Perrisoud. Morphine-6-glucuronide and morphine-3-glucuronide as molecular chameleons with unexpected lipophilicity. J. Med. Chem. 34: 1272-75 (1991).
34. G.W. Hanks and P.J. Wand. Enterohepatic circulation of opoid drugs: Is it clinically relevant in the treatment of cancer patients? Clin. Pharmacokinet. 17: 65-68 (1989).